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Effect of Oral Iron Repletion on Exercise Capacity
in Patients With Heart Failure With Reduced
Ejection Fraction and Iron Deficiency
The IRONOUT HF Randomized Clinical Trial
Gregory D. Lewis, MD; Rajeev Malhotra, MD; Adrian F. Hernandez, MD, MHS; Steven E. McNulty, MS;
Andrew Smith, MD; G. Michael Felker, MD, MHS; W. H. Wilson Tang, MD; Shane J. LaRue, MD;
Margaret M. Redfield, MD; Marc J. Semigran, MD; Michael M. Givertz, MD; Peter Van Buren, MD;
David Whellan, MD; Kevin J. Anstrom, PhD; Monica R. Shah, MD, MHS; Patrice Desvigne-Nickens, MD;
Javed Butler, MD; Eugene Braunwald, MD; for the NHLBI Heart Failure Clinical Research Network
Supplemental content
IMPORTANCE Iron deficiency is present in approximately 50% of patients with heart failure
with reduced left ventricular ejection fraction (HFrEF) and is an independent predictor of
reduced functional capacity and mortality. However, the efficacy of inexpensive readily
available oral iron supplementation in heart failure is unknown.
OBJECTIVE To test whether therapy with oral iron improves peak exercise capacity in patients
with HFrEF and iron deficiency.
DESIGN, SETTING, AND PARTICIPANTS Phase 2, double-blind, placebo-controlled randomized
clinical trial of patients with HFrEF (<40%) and iron deficiency, defined as a serum ferritin
level of 15 to 100 ng/mL or a serum ferritin level of 101 to 299 ng/mL with transferrin
saturation of less than 20%. Participants were enrolled between September 2014 and
November 2015 at 23 US sites.
INTERVENTIONS Oral iron polysaccharide (n = 111) or placebo (n = 114), 150 mg twice daily for

16 weeks.
MAIN OUTCOMES AND MEASURES The primary end point was a change in peak oxygen uptake
(V̇O2) from baseline to 16 weeks. Secondary end points were change in 6-minute walk
distance, plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and health
status as assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ, range 0-100, higher
scores reflect better quality of life).
RESULTS Among 225 randomized participants (median age, 63 years; 36% women) 203
completed the study. The median baseline peak V̇O2 was 1196 mL/min (interquartile range
[IQR], 887-1448 mL/min) in the oral iron group and 1167 mL/min (IQR, 887-1449 mL/min)
in the placebo group. The primary end point, change in peak V̇O2 at 16 weeks, did not
significantly differ between the oral iron and placebo groups (+23 mL/min vs −2 mL/min;
difference, 21 mL/min [95% CI, −34 to +76 mL/min]; P = .46). Similarly, at 16 weeks, there
were no significant differences between treatment groups in changes in 6-minute walk
distance (−13 m; 95% CI, −32 to 6 m), NT-proBNP levels (159; 95% CI, −280 to 599 pg/mL),
or KCCQ score (1; 95% CI, −2.4 to 4.4), all P > .05.
CONCLUSIONS AND RELEVANCE Among participants with HFrEF with iron deficiency,
high-dose oral iron did not improve exercise capacity over 16 weeks. These results do not
support use of oral iron supplementation in patients with HFrEF.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT02188784
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ron deficiency is the most common nutritional deficiency
worldwide, affecting more than 15% of the global population as of 20101 and approximately one-half of patients with
symptomatic heart failure.2 The presence of iron deficiency in
patients with heart failure, regardless of hemoglobin status,
is associated with reduced functional capacity, poorer quality of life, and increased mortality.2,3
Iron plays a critical role in systemic oxygen (O2) delivery
and utilization.3-6 Iron contributes to erythropoiesis and therefore iron deficiency decreases O2-carrying capacity of the blood
through reduced hemoglobin levels. Iron is also an obligate
component of enzymes involved in cellular respiration, oxidative phosphorylation, vascular homeostasis, nitric oxide generation, and the citric acid cycle.7,8 Hence, cells with highenergy demands, including skeletal and cardiac myocytes, are
particularly sensitive to depleted iron stores.9 Cardiac iron deficiency is present in patients with heart failure and associated with impaired mitochondrial function,10 abnormal sarcomere structure,5 and left ventricular systolic dysfunction.11,12
Despite growing recognition of the functional and prognostic significance of iron deficiency, randomized multicenter trials exploring the utility of oral iron supplementation, a therapy that is inexpensive, readily available, and safe,
have not been performed in patients with heart failure. Moreover, patient characteristics and biochemical profiles that may
influence responsiveness to oral iron in patients with heart failure have not been defined. Although results of intravenous iron
repletion trials have been favorable,13,14 regularly treating patients with intravenous iron products is expensive and poses
logistical challenges for outpatients. The Iron Repletion Effects on Oxygen Uptake in Heart Failure (IRONOUT HF) trial
was designed to test the hypothesis that, compared with placebo, oral iron repletion in heart failure patients with iron deficiency improves exercise capacity after 16 weeks of therapy.

Methods
Study Oversight
All study participants provided written informed consent prior
to enrollment. The National Heart, Lung, and Blood Institute–
sponsored Heart Failure Clinical Research Network investigators conceived, designed, and conducted this study. The trial
protocol was approved by a National Heart, Lung, and Blood
Institute–appointed protocol review committee and data and
safety monitoring board and by the institutional review board
at each participating site. The Duke Clinical Research Institute served as the coordinating center.

Study Design
The rationale and design of this study have been previously
described15 and are reported in the full protocol (see Supplement
1). Patients with reduced left ventricular ejection fraction (≤40%)
and heart failure (with New York Heart Association functional
class II through IV symptoms) (HFrEF) who were stable while
receiving medical therapy were eligible to participate if they had
objective evidence of iron deficiency (ferritin 15-100 ng/mL or
between 100-299 ng/mL with a transferrin saturation [Tsat] level

Key Points
Question Does therapy with oral iron improve exercise capacity in
patients with heart failure and iron deficiency?
Findings In this randomized clinical trial of 225 adults with heart
failure and reduced ejection fraction, oral iron polysaccharide
minimally repleted iron stores and had no significant effect on
exercise capacity at 16 weeks compared with placebo (+23 mL/min
for oral iron polysaccharide vs −2 mL/min for placebo).
Meaning These findings do not support the use of oral iron
supplementation in patients with heart failure and reduced left
ventricular ejection fraction and iron deficiency.

<20%) and hemoglobin levels between 9 and 15 g/dL (men) or
9 and 13.5 g/dL (women).15 Individuals were excluded if a neuromuscular, orthopedic, or other noncardiac condition prevented cardiopulmonary exercise testing (CPET). Inability to
achieve a respiratory exchange ratio greater than or equal to 1.0
on baseline screening CPET was also an exclusion criterion.
A complete list of the trial inclusion and exclusion criteria is provided in eTable 1 in Supplement 2.
Race, ethnicity, and sex were included as data elements
to satisfy the National Heart, Lung, and Blood Institute Policy
for Inclusion of Women and Minorities in Clinical Research.
Race, ethnicity, and sex determinations were provided by the
participants and collected as fixed categories. CPETs were performed by CPET Core Laboratory–certified sites using equipment and calibration approaches that met American Thoracic Society standards. CPETs were performed using a 10-W/
min incremental ramp protocol, and breath-by-breath
measures of oxygen uptake were uniformly analyzed by the
CPET Core Laboratory. Quality control measures included repeated physiologic calibration testing individuals who tested
within the normal range to ensure proper equipment calibration and performance. Participants who met screening criteria underwent baseline studies, including obtainment of medical history and physical examination, CPET, Kansas City
Cardiomyopathy Questionnaire (KCCQ),16 6-minute walk test,
and phlebotomy for biomarkers, and were then randomly assigned in a 1:1 ratio to receive either oral iron polysaccharide
or placebo with the use of an automated web-based system.
A permuted block-randomization method (4 participants/
block) was stratified by enrolling site and anemia status (defined as hemoglobin <12 g/dL).
Study drug was administered orally at 150 mg, twice daily
for 16 weeks. At the end of 8 weeks, medical history was again
recorded and participants underwent a physical examination, a 6-minute walk test, and completed a KCCQ quality of
life questionnaire. At the end of 16 weeks, each participant's
medical history, physical examination, KCCQ, CPET, and
6-minute walk test were repeated in the same order. If adverse effects developed, study personnel could recommend
a discontinuation of the study drug or a dose frequency reduction to once daily. Blinded central core laboratories assessed biomarkers (University of Vermont) and CPET end points
(Massachusetts General Hospital, Harvard University).
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Study End Points
The primary end point was the change in peak oxygen uptake
(peak V̇O2) after 16 weeks of therapy. Change in peak V̇O2 reflects the multiple mechanisms by which iron repletion is expected to improve systemic oxygen delivery and utilization
(previously described).15 There is also significant intrinsic value
to patients in improving impaired exercise capacity, a cardinal manifestation of heart failure.
Secondary end points included assessments of (1) submaximal exercise capacity, as measured by O2 uptake kinetics at initiation of exercise17; (2) ventilatory efficiency, as measured by minute ventilation relative to CO 2 production
throughout exercise; (3) 6-minute walk distance; (4) plasma
N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels; and (5) KCCQ. Exploratory objectives sought to determine if the following prespecified subgroups of patients would
derive differential benefit from oral iron: (1) patients with or
without anemia; (2) patients with or without venous congestion based on jugular venous pressure (>10 cm) or lower extremity edema; and (3) patients with and without a respiratory exchange ratio greater than 1.1 during both maximum
incremental exercise tests. Other exploratory objectives were
used to examine whether oral iron repletion influenced clinical outcomes: time to death, time to heart failure hospitalization, O2 uptake at the ventilatory threshold, and renal function (creatinine, cystatin C). Iron studies (iron, total iron binding
capacity, and ferritin) were measured at baseline and after 16
weeks of study medication to determine the extent to which
oral iron led to iron repletion in HFrEF patients.
Hepcidin is a hepatically derived peptide that inhibits intestinal iron absorption by interacting with its specific transmembrane receptor (ferroportin) on target cells. Hepcidin causes
reduced expression of ferroportin, which is responsible for importing systemic iron from enterocytes and also iron release from
the reticuloendothelial system.18-21 An iron-replete state stimulates hepcidin expression and reduces iron absorption. Iron
depletion suppresses hepcidin levels and enhances iron absorption. Inflammation can also induce hepcidin expression independent of iron stores and thus, inappropriately limit iron
absorption.22 Because heart failure is associated with increased inflammation, predisposing to hepcidin dysregulation, this study sought to determine if baseline hepcidin levels
predicted oral iron responsiveness. In addition, we measured
soluble transferrin receptor levels because elevated levels are
observed in states of high cellular avidity for iron, but whether
levels normalize with oral iron repletion is unknown.18 Therefore plasma hepcidin levels and soluble transferrin receptor levels were measured at baseline and after 16 weeks to gain mechanistic insight into oral iron responsiveness in heart failure.

Statistical Analysis
The full statistical analysis plan appears in Supplement 3. All primary analyses were based on the intention-to-treat principle,
meaning that study participants were analyzed as members of
the treatment group to which they were randomized regardless
of their adherence to or receipt of the intended treatment. A minimally important difference for peak V̇O2 of 1.0 mL/kg/min was
used based on a previously determined significant relationship
1960

Figure 1. Flow of Participants for the IRONOUT HF Study

225 Patients randomizeda

111 Randomized to receive iron
polysaccharide
111 Received at least 1 dose
of iron polysaccharide

114 Randomized to receive placebo
113 Received at least 1 dose
of placebo
1 Did not receive placebo
(physician decision)

96 Completed the study per protocol
15 Did not complete the study per
protocol (iron polysaccharide
discontinued prior to end
of study)
6 Incomplete exercise data• for
primary endpoint (peak VO2)
assessment
3 Withdrew consent
3 Died
3 Other

95 Completed the study per protocol
19 Did not complete the study per
protocol (placebo discontinued
prior to end of study)
9 Withdrew consent
6 Incomplete exercise data• for
primary endpoint (peak VO2)
assessment
3 Other
1 Died

111 Included in the primary analysis

114 Included in the primary analysis

Secondary end points were analyzed with multiple imputation techniques when
data were unavailable for the end point.
a

Data on patients screened for eligibility were not available.

between that change in peak V̇O2 and heart failure outcomes.23
Using an estimate of 2.0 mL/kg/min for the standard deviation
for peak V̇O2, a sample size of 172 participants (86 per group) provided 90% power to detect the minimally important difference
with a 2-sided type I error of .05. Allowing for 20% missing data
(to account for death, study withdrawal, or missing data) resulted
in a sample size of at least 108 per group.
Baseline data are presented as medians with interquartile
ranges (IQRs). A general linear model with the change in peak
V̇O2 measured at 16 weeks as the response variable and predictor variables including a treatment indicator and the baseline
measure of peak V̇O2 were used in the primary analysis. The primary analysis for peak V̇O2 used multiple imputation techniques to address incomplete data (statistical analysis plan in
Supplement 3). A sensitivity analysis of the peak V̇O2 outcome
used values from participants with complete data at baseline
and 16 weeks. A mixed-effects model was used to analyze site
effects for the primary end point. For primary and secondary
end points, P values less than .05 were considered statistically
significant with 2-sided significance testing. All analyses were
conducted using SAS statistical software, version 9.4.

Results
A total of 225 participants were enrolled (Figure 1) in the trial
from September 3, 2014, through November 18, 2015, at 23 sites
in the United States. Baseline characteristics are presented in
Table 1. The median age was 63 years and 36% of the participants were women. Median duration of heart failure was 5.7
years. Ischemic heart disease was the primary etiology of HFrEF
in 78% of participants. Despite high rates of guidelinedirected medical therapies for HFrEF, the median NT-proBNP
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Table 1. Baseline Characteristics of Participants in the IRONOUT HF Studya
Oral Iron
(n = 111)
63.0 (54-71)

Placebo
(n = 114)
63 (55-70)

All
(N = 225)
63 (55-70)

44 (40)

36 (32)

80 (36)

White

79 (71)

85 (75)

164 (73)

Black

31 (28)

26 (23)

57 (25)

Asian

1 (1)

2 (2)

3 (1)

More than 1 race

0

1 (1)

Age, median (IQR), y
Women
Race/ethnicityb

1 (1)

Body mass index, median (IQR)c

28.9 (25.3-33.7)

29.6 (25.9-33.8)

29.2 (25.7-33.8)

Left ventricular ejection fraction, median (IQR), %

25 (20-34)

25 (20-33)

25 (20-34)

II

81 (73)

69 (61)

150 (67)

III

30 (27)

45 (39)

75 (33)

KCCQ clinical score

77.1 (63.5-89.6)

74.2 (58.3-87.5)

75.5 (61.5-88.5)

KCCQ overall score

75.0 (59.6-87.3)

70.1 (50.8-85.4)

Functional Measures
New York Heart Association classification

Summary score, median (IQR)d

6-min walk distance, median (IQR), m

365 (304-433)

360 (273-428)

71.9 (56.0-85.9)
363 (292-428)

Physical examination
Weight, median (IQR), kg

86 (71-100)

90 (76-105)

90 (75-103)

112 (100-125)

112 (98-125)

112 (98-125)

Heart rate, median (IQR), beats/min

70 (64-77)

73 (64-80)

71 (64-79)

Elevated jugular venous pressure

13 (12)

13 (11)

26 (12)

Peripheral edema

14 (13)

9 (8)

23 (10)

Systolic blood pressure, median (IQR), mm Hg

Medical history
Time since diagnosis of heart failure, median (IQR), y

5.3 (1.4-10.3)

6.2 (2.0-9.8)

5.7 (1.9-10.0)

Prior hospitalization for heart failure within past year

46 (41)

51 (45)

97 (43)

Ischemic heart disease

86 (77)

89 (78)

175 (78)

Hypertension

80 (72)

82 (73)

162 (72)

Atrial fibrillation

43 (39)

43 (38)

86 (39)

Diabetes mellitus

38 (34)

50 (44)

88 (39)

Stage ≥3 chronic kidney diseasee

21 (19)

31 (27)

52 (23)
216 (96)

Heart failure medications at enrollment
β-Blocker

106 (95)

110 (96)

ACE inhibitor or ARB

98 (88)

91 (80)

189 (84)

Loop diuretic

96 (86)

89 (79)

185 (83)

Antiplatelet agent

74 (67)

79 (69)

153 (68)

Aldosterone antagonist

68 (61)

68 (60)

136 (60)

Anticoagulant agent

55 (50)

49 (43)

104 (46)

Digoxin

23 (21)

27 (24)

50 (22)

Long-acting nitrates

21 (19)

25 (22)

46 (20)

Hydralazine

15 (14)

18 (16)

33 (15)

Laboratory measurements, median (IQR)
Creatinine, mg/dL

1.3 (1.0-1.6)

1.2 (0.9-1.5)

Cystatin C, mg/L

1.1 (0.9-1.3)

1.1 (0.8-1.3)

1.1 (0.8-1.3)

1072 (413-2286)

1170 (527-2530)

1111 (453-2412)

NT-proBNP, pg/mLf

1.2 (1.0-1.5)

Hemoglobin, g/dL

12.6 (11.7-13.3)

12.7 (11.8-13.4)

12.6 (11.8-13.3)

Iron, μg/dLf

71 (59-89)

72 (53-94)

62 (51-78)

Total iron-binding capacity, μg/dLf

383 (350-434)

370 (336-415)

349 (305-392)

Ferritin, ng/mLf

75 (43-108)

70 (42-111)

69 (40-98)

Transferrin saturation, %f

19 (16-24)

20 (14-26)

18 (15-22)

Soluble transferrin receptor, mg/Lf

3.9 (3.2-4.8)

3.8 (2.9-4.8)

3.8 (3.1-4.8)

Hepcidin, ng/mLf

6.7 (3.4-11.3)

7.4 (3.6-11.6)

7.0 (3.5-11.4)
(continued)
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Table 1. Baseline Characteristics of Participants in the IRONOUT HF Studya (continued)
Oral Iron
(n = 111)

Placebo
(n = 114)

All
(N = 225)

1196 (887-1448)

1167 (887-1449)

1172 (887-1449)

CPET Measurements, Median (IQR)
Peak oxygen uptake, V̇O2, mL/min
Peak oxygen uptake, V̇O2, mL/kg/min
Peak respiratory exchange ratio
Ventilatory efficiency, VE/VCO2 slope

13.3 (11.4-15.8)

12.9 (10.5-15.6)

1.1 (1.1-1.2)

1.1 (1.1-1.2)

35 (29-40)

Mean response time, O2 uptake kinetics, s
Ventilatory threshold, mL/min

50 (43-58)

47 (40-58)

48 (43-58)

703 (580-853)

695 (540-852)

SI conversion factors: To calculate creatinine to μmol/L, multiply by 88.4;
ferritin to pmol/L, multiply by 2.247; iron and iron-binding capacity to μmol/L,
multiply by 0.179; hepcidin to nM, multiply by 0.358.
Data are reported as No. (%) unless otherwise indicated.

level at the time of enrollment was 1111 (IQR, 453-2412) pg/mL
and the median left ventricular ejection fraction was 25% (IQR,
20%-34%). Exercise capacity was reduced as evidenced by median peak V̇O2 of 13.2 (IQR, 11.1-15.7) mL/kg/min. Venous congestion was uncommon as only 12% of participants had jugular venous pressure elevation on examination, and 10% of
participants had at least mild peripheral edema. In the setting of low ferritin levels (median, 69 ng/mL [IQR, 40-98]) and
low Tsat levels (median, 18% [IQR, 15%-22%]), median hemoglobin levels were reduced at 12.6 (IQR, 11.8-13.3) g/dL. Levels
of soluble transferrin receptors, which increase during states
of iron deficiency and high cellular avidity for iron, were elevated with a median value of 3.8 (IQR, 3.1-4.8) mg/L. Plasma
levels of the iron regulatory peptide hepcidin were also elevated with a median value of 7.0 (IQR, 3.5-11.4) ng/mL. Use
of antiplatelet drugs (68%) and anticoagulants (46%) was common. There was no important differences in any of the baseline clinical, laboratory, or CPET characteristics between participants in the 2 treatment groups.
At least 1 dose of study medication was received by all participants randomized to receive oral iron and 113 of the 114 participants randomized to receive placebo (Figure 1). Frequency
of permanent study drug discontinuation prior to study termination were similar in the oral iron group (14%; 15 participants) and the placebo group (15%; 17 participants) (Figure 1),
and the hazard ratio for time to permanent study drug discontinuation (0.90 favoring oral iron [95% CI, 0.45 to 1.79]; P = .76)
did not significantly differ between groups.

Primary End Point
The median baseline peak V̇O2 was 1196 mL/min (IQR, 887 to
1448 mL/min) in the oral iron group and 1167 mL/min (IQR, 887
to 1449 mL/min) in the placebo group (Table 1). The primary end
point, change in peak V̇O2, did not differ between groups
(oral iron, +23 mL/min [95% CI, −84 to 142 mL/min] vs placebo, −2 mL/min [−110 to 104 mL/min]), with a between-group
difference of 21 mL/min (95% CI, [−34 to 76 mL/min]; P = .46;
Table 2). The mean treatment difference in peak V̇O2 between
1962

1.1 (1.1-1.2)
34 (30-40)

675 (509-841)

Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin II
receptor blocker; CPET, cardiopulmonary exercise test; IQR, interquartile range;
KCCQ, Kansas City Cardiomyopathy Questionnaire; NT-proBNP, N-terminal
pro-B-type natriuretic peptide; VE/VCO2, minute ventilation/carbon dioxide
elimination; V̇O2, oxygen uptake.

a

33 (30-39)

13.2 (11.1-15.7)

b

Race and ethnicity were self-reported.

c

Calculated as weight in kilograms divided by height in meters squared.

d

Higher scores indicate better function (range, 1-100).

e

Determined by enrollment site.

f

Determined by a central core laboratory. Normal reference ranges: iron,
60-170 μg/dL; total iron binding capacity, 240-450 μg/dL; ferritin,
100-300 ng/mL; transferrin saturation, 20%-50%; soluble transferrin
receptor, 0.9-2.3 mg/L; and hepcidin, <6 ng/mL when iron deficient.

oral iron and placebo was 0.3 mL/kg/min (95% CI, −0.27 to
0.87 mL/kg/min; P = .30) when peak V̇O2 was normalized to
body weight. Between-group differences in change in peak V̇O2
remained nonsignificant after adjustment for site effects using
mixed-effects modeling (oral iron, + 23 mL/min [95% CI, −28
to 75]; P = .37) and with sensitivity analyses using complete cases
(oral iron, +23 mL/min [95% CI, −33 to 80]; P = .42) and worstrank analyses (oral iron, 108 vs placebo, 95, with higher values
indicating greater positive change in peak V̇O2 [P = .46]). In prespecified subgroup analyses, the change in peak V̇O2 was not
significantly different between treatment groups in men vs
women, participants with or without hemoglobin level of less
than 12 g/dL in women and of less than 13.5 g/dL in men, participants with or without baseline venous congestion, or participants with and without peak respiratory exchange ratios
greater than 1.1 (a threshold indicative of maximum volitional
effort) 2 4 on baseline and 16-week CPETs (eFigure 1 in
Supplement 2).

Secondary End Points and Safety
At 16 weeks, there were no significant differences between
treatment groups in change in 6-minute walk distance (difference, −13 m [95% CI, −32 to 6 m]; P = .19), NT-proBNP levels
(159 pg/mL [−280 to 599 pg/mL]; P = .48), KCCQ score (1.0 [−2.4
to 4.4]; P = .57), O2 uptake kinetics (3 s [−2 to 8 s]; P = .19), or
ventilatory efficiency, as indicated by the slope of minute ventilation relative to carbon dioxide elimination (VE/VCO2 slope,
0.8 [−0.3 to 2.6]; P = .35). The rates of serious adverse events
observed with oral iron and placebo were similar, as reported
in Table 2 and in eFigure 2 and eTable 2 in Supplement 2. Time
to first adverse event did not differ between groups (hazard
ratio, 0.85 favoring oral iron [95% CI, 0.56-1.31]; P=.47).

Exploratory End Points
At 16 weeks, when compared with placebo, oral iron was associated with an increment in V̇O2 at the ventilatory threshold that was not statistically significant (+36.4 mL/min [−3.4
to 76.2 mL/min]; P = .07). There were no differences in change
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Table 2. Primary, Secondary, and Safety End Points
Median (IQR)
Week-16 Valuesa
Oral Iron

Placebo

Difference in Change
From Baseline
(95% CI)

P Value

Change From Baseline to Week 16
Placebo

Oral Iron

Primary End Point
Peak V̇O2 at 16 wk, mL/min

1218 (892 to 1500) 1187 (902 to 1425) 23 (−84 to 142)

−2 (−110 to 104)

21 (−34 to 76)

.46

Ppeak V̇O2 at 16 wk, mL/kg/min

13.5 (11.7 to 16.3) 13.0 (10.2 to 15.9) 0.20 (−1.1 to 1.6)

0.01 (−1.1 to 0.9)

0.30 (−0.27 to 0.87)

.30

380 (322 to 467)

376 (286 to 448)

15 (−17 to 55)

21 (−24 to 56)

−1 (−24 to 23)

.95

366 (315 to 456)

397 (299 to 472)

19 (−19 to 51)

32 (−12 to 66)

−13 (−32 to 6)

.19

52 (46 to 61)

47 (40 to 58)

2.5 (−7 to 9)

1 (−10 to 6)

3 (−2 to 8)

.19

−0.3 (−4.6 to 2.8)

0.8 (−0.3 to 2.6)

.35

Secondary End Points
6-Min walk distance
at 8 wk, m
6-Min walk distance
at 16 wk, m
Mean response time
(O2 uptake kinetics), s
Ventilatory efficiency
(VE/VCO2 slope)
NT-proBNP, pg/mL

34.8 (29.9 to 41.1) 33.5 (29.4 to 38.9) −0.3 (−3.0 to 2.1)

−37 (−412 to 363)

159 (−280 to 599)

.48

KCCQ clinical summary score
at 8 wkb
KCCQ clinical summary score
at 16 wkb
Exploratory End Points

81.3 (70.8 to 91.7) 75.0 (58.9 to 87.5) 5.2 (−2.1 to 12.5)

889 (376 to 2373)

1085 (447 to 2582) 4 (−342 to 288)

1.0 (−7.3 to 8.3)

3.4 (−0.4 to 7.2)

.08

80.7 (67.7 to 91.6) 77.1 (65.1 to 89.6) 3.1 (−4.2 to 13.5)

3.0 (−4.2 to 10.4)

1.0 (−2.4 to 4.4)

.57

Ventilatory threshold
at 16 wk, mL/min
Creatinine at 16 wk, mg/dL

685 (546 to 884)

−2 (−86 to 75)

36 (−3 to 76)

.07

Cystatin C at 16 wk, mg/L

1.06 (0.86 to 1.38) 1.02 (0.78 to 1.31) 0.02 (−0.04 to 0.09) 0.01 (−0.08 to 0.07) 0.03 (−0.01 to 0.08)

Safety End Points, No. (%)

Oral Iron

Placebo

OR (95% CI)

Adverse events

39 (35)

45 (39)

0.83 (0.48 to 1.43)

.50

Serious adverse events

11 (10)

10 (9)

1.14 (0.47 to 2.81)

.77

Permanent study drug discontinuation

15 (14)

17 (15)

0.90 (0.45 to 1.79)

.76

Death or cardiovascular rehospitalization 14 (13)

12 (11)

1.19 (0.55 to 2.59)

.64

714 (558 to 873)

22 (−49 to 127)

1.31 (1.01 to 1.56) 1.21 (0.90 to 1.49) 0.03 (−0.10 to 0.13) 0.00 (−0.10 to 0.11) −0.02 (−0.09 to 0.05) .65

Abbreviations: IQR, interquartile range; KCCQ, Kansas City Cardiomyopathy;
NT-proBNP, N-terminal pro-B-type natriuretic peptide; OR, odds ratio; V̇O2,
volume of oxygen uptake.

.12

a

Values are for measurements made at week 16 unless otherwise specified for
8 week measurements.

b

Higher scores indicate improved clinical status (range, 1-100).

Table 3. Levels of Iron Metabolism Markers According to Treatment Group
Median (95% CI)
Week-16 Values
Iron Indexes

Oral Iron

Change From Baseline to Week 16
Placebo

Iron, μg/dL

80 (59 to 99)

72 (58 to 90)

TIBC, μg/dL

371 (336 to 405)

374 (339 to 428)

Oral Iron
6 (−12 to 29)
−12 (−43 to 5)

Tsat, %

22 (16 to 28)

20 (15 to 25)

2 (−3 to 7)

Ferritin, ng/ml

95 (58 to 134)

75 (42 to 123)

18 (−8 to 38)

Placebo

Difference in Change
From Baseline
(95% CI)

P Value

1 (−23 to 18)

11.0 (2.8 to 19.1)

.009

−0.5 (−22 to 17)

−13.4 (−22.2 to −4.6)

.003

0 (−5 to 5)
1 (−15 to 17)

3.3 (1.1 to 5.4)

.003

11.3 (−0.3 to 22.9)

.06

Hepcidin, ng/ml

8.9 (5.0 to 14.3)

7.8 (4.2 to 12.7)

1.7 (−1.0 to 5.6)

−0.3 (−3.2 to 3.1)

1.5 (−0.6 to 3.7)

.17

sTfR, mg/L

3.7 (2.9 to 4.4)

3.9 (3.1 to 4.8)

−0.3 (−0.8 to 0.1)

0.0 (−0.5 to 0.4)

−0.3 (−0.6 to −0.1)

.01

Abbreviations: sTfR, soluble transferrin receptor; TIBC, total iron binding capacity; Tsat, transferrin saturation.

in renal function between groups: creatinine (−0.02 mg/dL
[−0.09 to 0.05 mg/dL]; P = .65) and cystatin C (0.03 mg/L [−0.01
to 0.08 mg/L]; P = .12).
Iron Bioavailability
Measures of exercise capacity (peak V̇O2 [r = 0.17; P = .01];
6-minute walk distance [r = 0.28; P < .001]), NT-proBNP
(r = −0.16; P = .02), and KCCQ Clinical Summary score (r = 0.28;
P < .001) were all correlated with baseline Tsat levels (18% [IQR,
15% to 22%]).
Compared with placebo, oral iron increased Tsat levels
(+3.3% [95% CI, 1.1% to 5.4%]; P = .003) and ferritin levels

(+11.3 ng/mL [−0.3 to 22.9 ng/mL]; P = .06) (Table 3 and eTable
2 in Supplement 2). Levels of soluble transferrin receptors decreased in participants treated with oral iron when compared
with placebo (−0.3 mg/L [95% CI, −0.6 to −0.1 mg/L]; P = .01,
Table 3). Participants in the highest quartile of response in Tsat,
in response to oral iron, demonstrated improvement in KCCQ
clinical summary scores (5.2 [95% CI, 0.1 to 10.4]; P = .047),
and an increase in V̇O2 at the ventilatory threshold (58 mL/min
[95% CI, −7 to 123 mL/min]; P = .08) that was not statistically
significant. Changes in peak V̇O2 (r = 0.16; P = .03) and in
NT-proBNP (r = −0.18; P = .02) correlated directly with change
in Tsat.
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Figure 2. Relationships Between Quartiles of Baseline Plasma Hepcidin Levels and Response in Participants Treated With Iron Polysaccharide
A Transferrin saturation change from

B

baseline to wk 16
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P values indicate differences across all 4 quartiles using the Wilcoxon rank-sum test.

Responders to Oral Iron Therapy
Median hepcidin levels increased from 6.7 to 8.9 ng/mL
(+1.7 ng/mL [95% CI, −1.0 to 5.6 ng/mL]; P = .007) in the oral
iron group, consistent with the anticipated response to increased iron exposure, and remained unchanged in the placebo group (7.4 to 7.8 ng/mL; −0.3 ng/mL [95% CI, −3.2 to
3.1 ng/mL]; P = .91). The between-group comparison of change
in hepcidin levels was not statistically significant (+1.5 ng/mL
[95% CI, −0.6 to 3.7 ng/mL]; P = .17 [Table 3]).
In response to 16 weeks of oral iron across quartiles of
increasing baseline hepcidin levels, there were reduced increments in Tsat and ferritin and a blunted fall in soluble
transferrin receptor levels (Figure 2). Changes in Tsat (r = −0.29;
P = .004), ferritin (r = −0.30; P = .004), and soluble transferrin receptor levels (r = 0.48; P < .001) at 16 weeks were correlated with baseline hepcidin levels.

Discussion
High-dose oral iron did not improve exercise capacity in
patients with iron deficiency and HFrEF. The lack of effect of
oral iron on exercise capacity, including peak V̇O 2 and
6-minute walk distance, and quality of life scores (KCCQ)
stands in contrast to results from trials of intravenous iron
repletion in similar patient populations.13,14,25 Also in contrast to previous studies with intravenous iron repletion, in
this study, oral iron therapy produced minimal improvement
in iron stores, implicating the route of administration rather
than the strategy of iron repletion in the lack of clinical benefit. The significant relationship between higher baseline
hepcidin levels and lack of iron repletion provides mechanistic insight into this study’s observed findings.
With the exception of one study that included 7 individuals randomized to receive oral iron,26 this is the first multicenter randomized clinical trial exploring the utility of oral iron
1964

supplementation in HFrEF patients with iron deficiency. In
light of the failure of oral iron to improve measures of functional capacity in this study, a comparison of the patient populations and relative changes in iron stores to trials of intravenous iron repletion is warranted.
The patient population in this study was similar to that
investigated in trials of intravenous iron repletion (FAIR-HF
[Ferinject Assessment in Patients With Iron Deficiency and
Chronic Heart Failure] and CONFIRM-HF [Ferric Carboxymaltose Evaluation on Performance in Patients With Iron
Deficiency in Combination with Chronic Heart Failure])13,14
in patient age and body mass index, as well as underlying
heart failure etiology and baseline pharmacotherapy. In
addition, baseline laboratory indices of iron stores were
similar across the 3 studies. However, iron indices following
oral repletion, as compared with intravenous iron repletion,
differed markedly (eTable 3 in Supplement 2). Despite
administering approximately 15-fold more iron orally in this
study than that administered intravenously in FAIR-HF
(ie, 33.6 g vs ≈ 2 g), there was only a modest 3%-median
increment in Tsat and 11-ng/mL increment in ferritin in participants randomized to receive oral iron vs placebo in this
study, compared with a 70%-median increment in Tsat and
a 550%-increment in ferritin with intravenous iron administration in the FAIR-HF Trial.13
There are several potential explanations for failure of oral
iron to improve iron stores and exercise capacity in this trial.
Hepcidin plays a critical role in inhibiting iron absorption.18-21
In this study, participants with higher baseline hepcidin levels demonstrated reduced Tsat and ferritin augmentation and
an attenuated decline in soluble transferrin receptor levels in
response to 16 weeks of oral iron supplementation (Figure 2).
Taken together, these findings indicate that higher hepcidin
levels may limit responsiveness to oral iron. Expected hepcidin levels in individuals with iron deficiency and anemia are
lower than the values measured in this study.27,28
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Other potential mediators of refractoriness to oral iron in
heart failure seem less likely to have affected our findings. Use
of anticoagulants and antiplatelet agents was prevalent, but the
rate of expected loss of iron (1-1.5 mg/d) is markedly less than the
repletion dose (300 mg/d) administered. Therefore, in the absence of overt gastrointenstinal bleeding, which did not occur
in any of the participants treated with oral iron during the trial,
blood loss would not be expected to account for the observed
minimal increases in iron stores with oral iron treatment.
The choice of iron polysaccharide formulation for this
study was based on its offering the highest dose of elemental
iron among available oral supplements, coupled with its tolerance profile to aid in adherence and minimize risk of unblinding participants. Polysaccharide iron preparations have
been shown to provide comparable iron repletion to iron
salts.29-31 Recommended daily oral iron intake is 8 to 18 mg.
Hence, even after accounting for limited gastrointestinal iron
absorption, the 20-fold increase in oral iron exposure, compared with the recommended daily intake, served to adequately test the hypothesis that oral iron supplementation
would improve iron stores and functional capacity in HFrEF.
The low incidence of oral iron discontinuation, which was 14%
among participants receiving iron and 15% in the placebo group,
argues against the observed findings being related to lack of
adherence with oral iron.
The selection of change in peak V̇O2 for the primary end
point, as previously described,15 was based on the fact that peak
V̇O2 is the gold standard indicator of functional capacity in heart
failure and has been shown to improve with iron repletion in
non–heart failure populations. The lack of treatment effect on
quality of life, NT-proBNP, and other physiological end points
is consistent with the observed lack of treatment effect on
maximal exercise capacity. The exploratory end point, change
in V̇O2 at the ventilatory threshold, showed a 5% increment in
the iron group and no change in placebo, although the study
may have been underpowered for this modest betweengroup difference to reach significance (P = .08). Submaxi-
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